文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

IL-1β抑制对随机CANTOS试验中贫血和克隆性造血的影响

Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial.
PubMed 文献 · Blood Adv · 2023-01-01

基于CANTOS试验4595例患者的蛋白基因组学分析,评估卡那奴单抗(靶向IL-1β的单克隆抗体)对贫血和克隆性造血(CH)的影响。CH突变存在时贫血更常见,但卡那奴单抗治疗可降低贫血;在合并CH突变和贫血的患者中,卡那奴单抗与更高的血红蛋白增幅显著相关。卡那奴单抗抑制铁调素、促炎细胞因子、髓系活化和补体通路,并在合并CH突变和贫血的患者中更大程度逆转病理失调通路。

要点

  • CH突变存在时贫血更常见,但卡那奴单抗治疗可降低贫血发生。
  • 合并CH突变和贫血的患者中,卡那奴单抗与更高的血红蛋白增幅显著相关。
  • 卡那奴单抗抑制铁调素、促炎细胞因子、髓系活化和补体通路。

核心结论

  • 这些分子发现为IL-1β阻断的临床使用提供了证据,并支持进一步研究卡那奴单抗用于合并贫血和CH突变的患者。

研究设计与样本

  • 当前蛋白基因组学分析纳入CANTOS研究4595例接受卡那奴单抗或安慰剂治疗的患者,使用SomaScan评估多重蛋白质组学(4785种蛋白质)并对CH突变进行靶向深度测序。
  • 研究在www.clinicaltrials.gov注册为#NCT01327846。

主要发现

  • CH突变存在时贫血更常见,但卡那奴单抗治疗可降低贫血。
  • 卡那奴单抗治疗与合并CH突变和贫血的患者相比CH突变无贫血或无CH突变患者有显著更高的血红蛋白增幅相关。
  • 与无CH突变者相比,CH突变存在与炎症和感染防御反应的蛋白质组学特征以及高风险心血管疾病标志物相关,贫血的存在进一步增强了这些特征。
  • 卡那奴单抗抑制铁调素、促炎细胞因子、髓系活化和补体通路,并在合并CH突变和贫血的患者中更大程度逆转病理失调通路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Canakinumab, a monoclonal antibody targeting proinflammatory cytokine interleukin-1β (IL-1β), improved hemoglobin levels while preventing recurrent cardiovascular events in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). This cardiovascular (CV) preventive effect was greater in patients with TET2 mutations associated with clonal hematopoiesis (CH). The current proteogenomic analysis aimed to understand the clinical response to canakinumab and underlying proteomic profiles in the context of CH and anemia. The analysis included 4595 patients from the CANTOS study who received either canakinumab or placebo and evaluated multiplexed proteomics (4785 proteins) using SomaScan and targeted deep sequencing for CH mutations. Incident anemia was more common in the presence of CH mutations but reduced by canakinumab treatment. Canakinumab treatment was significantly associated with higher hemoglobin increment in patients with concurrent CH mutations and anemia than patients with CH mutations without anemia or without CH mutations. Compared with those without CH mutations, the presence of CH mutations was associated with proteomic signatures of inflammation and defense response to infection, as well as markers of high-risk CV disease which was further enhanced by the presence of anemia. Canakinumab suppressed hepcidin, proinflammatory cytokines, myeloid activation, and complement pathways, and reversed pathologically deregulated pathways to a greater extent in patients with CH mutations and anemia. These molecular findings provide evidence of the clinical use of IL-1β blockade and support further study of canakinumab for patients with concurrent anemia and CH mutations. This study was registered at www.clinicaltrials.gov as #NCT01327846.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Woo J, Lu D, Lewandowski A, et al. Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial. Blood Adv. 2023. PMID: 37934948. doi:10.1182/bloodadvances.2023011578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。